Maria Walsh lands promotion at Janssen UK

27 July 2022

The Johnson & Johnson (NYSE: JNJ) subsidiary Janssen UK has named Maria Walsh its business unit director, oncology and hematology, cell and gene therapy and pulmonary hypertension.

Ms Walsh, who joined the company in May 2020 as commercial lead in hematology, will transition to her new role and join the Janssen UK leadership team.

"Maria is not only an experienced leader in oncology, she is also a strategic thinker with an empathic and thoughtful management style"Before joining Janssen, Ms Walsh worked in marketing, sales, medical and market access roles at all stages of the product lifecycle, with a focus on oncology. Her previous employers include leading pharma companies Bristol Myers Squibb (NYSE: BMS), Merck KGaA (MRK: DE) and Sanofi (Euronext: SAN).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK